Overview

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
Celgene Corporation
Treatments:
Capecitabine
Thalidomide